López González, A.; Del Barco Berrón, S.; Grau, I.; Galan, M.; Castelo Fernández, B.; Cortés, A.; Sánchez Rovira, P.; Martinez-Bueno, A.; Gonzalez, X.; GarcÃa, A.;
et al. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 2022, 14, 5880.
https://doi.org/10.3390/cancers14235880
AMA Style
López González A, Del Barco Berrón S, Grau I, Galan M, Castelo Fernández B, Cortés A, Sánchez Rovira P, Martinez-Bueno A, Gonzalez X, GarcÃa A,
et al. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers. 2022; 14(23):5880.
https://doi.org/10.3390/cancers14235880
Chicago/Turabian Style
López González, Ana, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Alfonso Cortés, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena GarcÃa,
and et al. 2022. "Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study" Cancers 14, no. 23: 5880.
https://doi.org/10.3390/cancers14235880
APA Style
López González, A., Del Barco Berrón, S., Grau, I., Galan, M., Castelo Fernández, B., Cortés, A., Sánchez Rovira, P., Martinez-Bueno, A., Gonzalez, X., GarcÃa, A., Gener, P., Mina, L., Alcalá-López, D., Sampayo, M., Cortés, J., Pérez-Garcia, J. M., Llombart-Cussac, A., & López-Miranda, E.
(2022). Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers, 14(23), 5880.
https://doi.org/10.3390/cancers14235880
